CY1108725T1 - Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer - Google Patents

Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer

Info

Publication number
CY1108725T1
CY1108725T1 CY20091100080T CY091100080T CY1108725T1 CY 1108725 T1 CY1108725 T1 CY 1108725T1 CY 20091100080 T CY20091100080 T CY 20091100080T CY 091100080 T CY091100080 T CY 091100080T CY 1108725 T1 CY1108725 T1 CY 1108725T1
Authority
CY
Cyprus
Prior art keywords
alzheimer
treatment
combination
acetylcholinesterase inhibitors
nmda antagonist
Prior art date
Application number
CY20091100080T
Other languages
English (en)
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29713304&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1108725(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of CY1108725T1 publication Critical patent/CY1108725T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Φαρμακευτική σύνθεσις περιλαμβάνουσα (α) αποτελεσματικήν ποσότητα ενός ή περισσοτέρων αναστολέως (ή αναστολέων) ακετυλοχολινεστεράσης ή φαρμακευτικώς αποτελεσματικού άλατος αυτού, και (β) αποτελεσματικήν ποσότητα ενός ή περισσοτέρων ανταγωνιστού (ή ανταγωνιστών) NMDA.
CY20091100080T 2002-05-31 2009-01-21 Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer CY1108725T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38446702P 2002-05-31 2002-05-31
DKPA200200844 2002-05-31
EP03724895A EP1509232B1 (en) 2002-05-31 2003-05-22 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CY1108725T1 true CY1108725T1 (el) 2014-04-09

Family

ID=29713304

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100080T CY1108725T1 (el) 2002-05-31 2009-01-21 Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer

Country Status (17)

Country Link
EP (1) EP1509232B1 (el)
JP (1) JP2005528431A (el)
AT (1) ATE414519T1 (el)
AU (1) AU2003227516B2 (el)
BR (1) BR0311375A (el)
CY (1) CY1108725T1 (el)
DE (1) DE60324788D1 (el)
DK (1) DK1509232T3 (el)
ES (1) ES2314200T3 (el)
IL (1) IL165255A0 (el)
MX (1) MXPA04011762A (el)
NO (1) NO332754B1 (el)
NZ (1) NZ536603A (el)
PL (1) PL373903A1 (el)
PT (1) PT1509232E (el)
SI (1) SI1509232T1 (el)
WO (1) WO2003101458A1 (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
EP1703902B1 (en) * 2004-01-05 2010-11-03 Merz Pharma GmbH & Co. KGaA Memantine for the treatment of mild-to-moderate alzheimer's disease
WO2005070429A1 (en) * 2004-01-22 2005-08-04 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
EP1740172A4 (en) * 2004-03-19 2007-10-10 Axonyx Inc ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
BRPI0518483A2 (pt) * 2004-11-23 2008-11-18 Neuromolecular Pharmaceuticals Inc composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
JP5666087B2 (ja) * 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
CA2604617C (en) * 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
CN102883601A (zh) 2009-12-02 2013-01-16 阿达玛斯医药公司 金刚烷胺组合物及其使用方法
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US9636445B2 (en) 2010-07-05 2017-05-02 Gambro Lundia Ab Ambulatory ultrafiltration device with control unit programmed to control a drive fluid pump to perform ultrafiltration
TR201007110A2 (tr) 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sinerjik etki gösteren kombinasyonlar
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
FR2983732B1 (fr) * 2011-12-09 2013-11-22 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}pharmaceutiques qui la contiennent
WO2013160728A1 (en) * 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
WO2014035355A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Pharmaceutical combination comprising idebenone and memantine
WO2014055047A1 (en) * 2012-08-31 2014-04-10 Mahmut Bilgic Combination of idebenone and donezepil
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
AP2015008498A0 (en) * 2012-12-13 2015-05-31 Lundbeck & Co As H Compositions comprising vortioxetine and donepezil
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CA3023836C (en) * 2016-05-18 2019-08-27 Suven Life Sciences Limited Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
WO2018081508A1 (en) * 2016-10-28 2018-05-03 Chase Pharmaceutical Corporation Memantine combinations and use
TR201619184A2 (tr) 2016-12-22 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Donepezi̇l ve memanti̇n i̇çeren kapsül bi̇leşi̇mleri̇
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2020240505A1 (en) 2019-05-31 2020-12-03 TECNIMEDE - Sociedade Técnico-medicinal, SA Immediate release fixed-dose combination of memantine and donepezil

Also Published As

Publication number Publication date
WO2003101458A1 (en) 2003-12-11
PL373903A1 (en) 2005-09-19
NZ536603A (en) 2007-06-29
JP2005528431A (ja) 2005-09-22
SI1509232T1 (sl) 2009-04-30
DK1509232T3 (da) 2009-02-23
AU2003227516B2 (en) 2008-03-20
EP1509232B1 (en) 2008-11-19
DE60324788D1 (de) 2009-01-02
PT1509232E (pt) 2009-01-07
NO20045434L (no) 2004-12-13
IL165255A0 (en) 2005-12-18
AU2003227516A1 (en) 2003-12-19
NO332754B1 (no) 2013-01-07
BR0311375A (pt) 2005-03-15
ATE414519T1 (de) 2008-12-15
EP1509232A1 (en) 2005-03-02
ES2314200T3 (es) 2009-03-16
MXPA04011762A (es) 2005-03-31

Similar Documents

Publication Publication Date Title
CY1108725T1 (el) Συνδυασμος ανταγωνιστου-nmda και αναστολεων ακετυλοχολινεστερασης δια την θεραπειαν της νοσου alzheimer
CY1110385T1 (el) Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
BR0317715A (pt) Composições e processos de uso de collajolie
CO5600999A2 (es) Composiciones farmaceuticas que comprenden inhibidores de valsartan y endopeptidasa neutra
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
DE60202452D1 (de) Pyridazinonaldose reductase inhibitoren
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MXPA04002167A (es) Inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
DK1564210T5 (da) 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
PL361404A1 (en) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
UY27991A1 (es) Derivados de pirrolidona domo inhibidores de maob
WO2003065987A3 (en) Granzyme b inhibitors
ATE273699T1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
SE0101932D0 (sv) Pharmaceutical combinations
GB0002336D0 (en) Medicaments
DE60228567D1 (de) Behandlung von hyperlipidämie
HUP0401854A2 (hu) COX-2 inhibitorokat és aszpirint tartalmazó kombinációk
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
EE05534B1 (et) IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора